DailyStocks Stock Article Search

https://www.entrepreneur.com/es/marketing/esta-es-la-combinacion-de-seo-que-necesitas-para-vencer-al/471202 Mar 14, 2024 - Para obtener una presencia en línea que brinde resultados y altas clasificaciones a largo plazo, crea una estrategia que se centre en combinar las mejores prácticas de SEO y las directrices de E-A-T (Experiencia, Autoridad, Confianza) — aquí te decimos cómo. 0

https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446 Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 0

https://seekingalpha.com/article/4678703-poseida-april-2024-data-could-shed-light-on-differentiated-car-t-advancement?source=feed_all_articles Mar 16, 2024 - Poseida is expected to release results from the phase 1 study using P-BCMA-ALLO1 on April 8th, 2024. Read why PSTX stock is a Buy. 0

https://seekingalpha.com/news/4080447-citius-pharmaceuticals-receives-fda-acceptance-of-resubmission-for-its-relapsed-lymphoma-treatment?source=feed_sector_healthcare Mar 18, 2024 - Citius Pharmaceuticals announces FDA acceptance of resubmission for LYMPHIR, a promising immunotherapy for cutaneous T-cell lymphoma treatment. 0

https://www.zacks.com/stock/news/2242974/5-reasons-to-invest-in-t-rowe-price-trow-stock-right-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242974 Mar 19, 2024 - T. Rowe Price's (TROW) solid AUM balance, business diversification initiatives, acquisitions and global reach make it an attractive investment option. 0

https://seekingalpha.com/news/4081853-bristol-myers-gets-eu-approval-for-abecma-for-multiple-myeloma?source=feed_sector_healthcare Mar 20, 2024 - Bristol Myers (BMY) has received EU regulatory approval for its CAR T-cell therapy Abecma in the treatment of relapsed or refractory multiple myeloma. Read more here. 0

https://www.nrn.com/quick-service/subway-plans-four-sauces-grocery-sales Mar 20, 2024 - Restaurant brand teams with T. Marzetti Co. for scholarship fund benefit 0

https://www.zacks.com/stock/news/2243567/is-it-wise-to-retain-sba-communications-sbac-stock-for-now?cid=CS-ZC-FT-analyst_blog|zer_report_update-2243567 Mar 20, 2024 - SBA Communications (SBAC) is likely to benefit from the rising global demand for wireless connectivity and its asset buyouts. However, notable customer concentration and high interest rates are key woes. 0

https://www.zacks.com/stock/news/2244198/biotech-stock-roundup-gern-crnx-gain-on-updates-bmy-s-car-t-cell-therapy-news-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2244198 Mar 21, 2024 - Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates. 0

https://www.fool.com/investing/2024/03/24/a-once-in-a-generation-investment-opportunity-1-ai/?source=iedfolrf0000001 Mar 24, 2024 - Brookfield Infrastructure offers a unique way to invest in the data infrastructure megatrend. 0